Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 19

Results For "Head"

1546 News Found

IDEAYA Biosciences enters license with Hengrui Pharma for a novel phase 1 DLL3 Topo-I-Payload ADC targeting SCLC and NET solid tumors
News | December 31, 2024

IDEAYA Biosciences enters license with Hengrui Pharma for a novel phase 1 DLL3 Topo-I-Payload ADC targeting SCLC and NET solid tumors

Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)


Schizophrenia in Children: Understanding Early-Onset Schizophrenia
News | December 31, 2024

Schizophrenia in Children: Understanding Early-Onset Schizophrenia

Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia


SVU to organise International Conference on Clinical Translation of Biomaterial-based Therapeutics and Devices on 6-7 Feb, 2025
News | December 26, 2024

SVU to organise International Conference on Clinical Translation of Biomaterial-based Therapeutics and Devices on 6-7 Feb, 2025

The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”


Lonza expands capsule manufacturing capacity in India and China
News | December 21, 2024

Lonza expands capsule manufacturing capacity in India and China

New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou


Kenvue India presents report on ‘The Hydration Gap for Non-Diarrheal Illnesses’
News | December 20, 2024

Kenvue India presents report on ‘The Hydration Gap for Non-Diarrheal Illnesses’

The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery


Glenmark USA launches Lacosamide Oral Solution, 10 mg/mL
News | December 17, 2024

Glenmark USA launches Lacosamide Oral Solution, 10 mg/mL

According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million


Merck to discontinue KeyVibe and Keyform clinical trials
Diagnostic Center | December 17, 2024

Merck to discontinue KeyVibe and Keyform clinical trials

Merck has also decided to end the favezelimab clinical development program


Merck to acquire HUB Organoids to advance cell culture portfolio
News | December 17, 2024

Merck to acquire HUB Organoids to advance cell culture portfolio

Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development


Bayer announces positive topline resukts for Aflibercept 8 mg in phase III study
Diagnostic Center | December 17, 2024

Bayer announces positive topline resukts for Aflibercept 8 mg in phase III study

Demonstrates vision gains with extended treatment intervals in retinal vein occlusion


Jitendra Singh releases landmark RSSDI study ' Indian Prevention of Diabetes Study (IPDS) on Yoga and Diabetes Prevention'
Healthcare | December 16, 2024

Jitendra Singh releases landmark RSSDI study ' Indian Prevention of Diabetes Study (IPDS) on Yoga and Diabetes Prevention'

A 40 minute daily Yoga routine, incorporating select asanas and pranayama, along with standard lifestyle interventions, can reduce the risk of developing diabetes by approximately 40%